Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc.’s Chief Financial Officer Sara Bonstein reported an automatic sale of shares tied to equity compensation. On the reported date, 2,404 shares of common stock were sold at $102.27 per share. According to the footnote, the shares were sold to satisfy tax withholding obligations when Restricted Stock Units vested and to cover related broker fees, rather than as a discretionary portfolio move. After this transaction, Bonstein directly owned 69,082 Insmed shares, so the filing mainly reflects routine tax handling on stock-based compensation.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of company stock mainly to cover taxes on vesting equity.
He sold 2,159 shares of Common Stock at $102.27 per share to satisfy tax withholding obligations from vested Restricted Stock Units and related broker fees. After this transaction, he directly holds 39,454 shares, so the sale represents only a portion of his overall stake and is characterized as a tax-related, administrative transaction rather than a discretionary reduction in ownership.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company common stock. On June 3, 2026, he sold 7,605 shares of common stock at $102.27 per share. According to the footnote, these shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, meaning this was a tax-related sale rather than a discretionary trade. Following the transaction, Lewis held 265,432 shares directly and 233,924 shares indirectly through a trust.
Insmed Inc.’s Chief Medical Officer, Dr. Martina Flammer, reported two small open-market sales of common stock made to cover taxes on equity compensation. She sold 2,566 shares at $102.27 on June 3 and 1,858 shares at $103.78 on June 5, totaling 4,424 shares. After these transactions, she directly holds 60,486 shares of Insmed common stock. The footnotes state the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees, and that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025.
INSMED Inc officer Sara Bonstein reported an intended sale of 2,404 common shares, with an aggregate market value of $245,857 and an approximate sale date of June 3, 2026. Merrill Lynch is named as the broker. Bonstein acquired 2,404 shares from the issuer through stock plan activity on June 1, 2026. She also sold 8,272 common shares on May 13, 2026, for gross proceeds of $961,020.
INSMED Inc officer Martina Flammer reported a proposed sale of 2,566 common shares, with an aggregate market value of $262,424 and an approximate sale date of June 3, 2026. The shares were acquired from the issuer through stock plan activity on June 1, 2026.
INSM submitted a Form 144 notice reporting a proposed sale of 2,370 shares of Common Stock as Stock Plan Activity dated 06/01/2026.
The excerpt also lists sales by Roger Adsett: 5,837 shares on 05/13/2026 and 88,060 shares on 04/01/2026. Shares outstanding are shown as 216,752,451 as of 06/03/2026.
INSMED Inc officer Michael Smith reported a proposed sale of 2,159 common shares, with an aggregate market value of $220,800 and an approximate sale date of June 3, 2026. Merrill Lynch is named as the broker.
The shares were acquired from the issuer through stock plan activity on June 1, 2026. The notice also lists sales by Michael Smith of 6,149 shares on May 22, 2026, for gross proceeds of $666,951; 4,109 shares on May 13, 2026, for $477,373; and 19,638 shares on March 30, 2026, for $2,964,929.
INSMED Inc officer William Lewis reported a proposed sale of 7,605 common shares, with an aggregate market value of $777,763 and an approximate sale date of June 3, 2026. Merrill Lynch is named as the broker. Lewis acquired 7,605 shares from the issuer through stock plan activity on June 1, 2026. Earlier sales by Lewis are also listed, dated March 5 through May 18, 2026.
Michael Smith, an officer of INSMED Inc., reported a proposed sale of 6,149 shares of common stock, with an approximate sale date of May 22, 2026 and an aggregate market value of $666,951. The stated Rule 10b5-1 plan adoption or instruction date is November 7, 2025. The shares were acquired from the issuer through stock plan activity on May 11, 2026.
The notice also lists Michael Smith’s prior common-stock sales: 4,109 shares for gross proceeds of $477,373 on May 13, 2026; 19,638 shares for $2,964,929 on March 30, 2026; and 24,774 shares for $3,859,153 on February 24, 2026.